Person: ERSOY, YELIZ EMINE
5 results
Search Results
Now showing 1 - 5 of 5
Publication Metadata only p53 expression and relationship with MDM2 amplification in breast carcinomas(2016-04-01) Buyukpinarbasili, NUR; Gucin, ZÜHAL; Ersoy, YELİZ EMİNE; ILBAK, Ayca; Kadioglu, HÜSEYİN; Muslumanoglu, Mahmut; BÜYÜKPINARBAŞILI, NUR; GÜCİN, ZÜHAL; ERSOY, YELIZ EMINE; KADIOĞLU, HÜSEYİNCarcinoma of the breast, like other malignancies, is a genetic disease with multiple genetic events leading to the malignant phenotype. p53 mutations are the most common genetic events in human cancer. Inactivation of p53 can be a result of mutation in gene sequence. One of the main structures that regulate p53 stabilization is MDM2. It suppresses p53 transcriptional activation by recognizing transactivation domain of p53. The loss of MDM2 function on p53 regulation results in deprivation of p53 tumor suppressor ability. Single nucleotide polymorphisms (SNP309 T->G exchange) or MDM2 amplification has been proposed to play a role in this issue. In the present study, our aim is to analyze p53 and MDM2 status and investigate their interactions in human sporadic breast carcinoma. The study groups were separated according to their molecular classifications. In each group, histologic type of the tumor, conventional prognostic parameters, p53, and MDM2 interactions were compared statistically. Tumors are divided into 4 subtypes due to estrogen and progesterone receptor status, HER-2, and Ki-67 proliferation index results. According to this classification, 23 cases are in the luminal A, 32 cases are in the luminal B, 15 cases are in the HER-2 positive, and 22 cases are in the triple-negative group, with a total of 92 cases. p53 expression is low in luminal breast carcinomas than HER-2 and triple-negative subtypes. MDM2 amplification frequency was found to be 5.4% in total. MDM2 gene amplification does not have a significant role in breast carcinogenesis, but other possible mechanisms may play a role in its inactivation. (C) 2016 Elsevier Inc. All rights reserved.Publication Metadata only Comment on: Actinomycotic Infection of the Abdominal Wall Mimicking a Malignant Neoplasm by Yi et al.(2012-12-01) Kadioglu, HÜSEYİN; Ersoy, YELİZ EMİNE; Bozkurt, SÜLEYMAN; Memmi, NAİM; CIPE, Gokhan; Gucin, ZÜHAL; MUSLUMANOGLU, Mahmut; KADIOĞLU, HÜSEYİN; ERSOY, YELIZ EMINE; BOZKURT, SÜLEYMAN; MEMMİ, NAİM; GÜCİN, ZÜHALPublication Open Access The correlation between breast cancer and urinary iodine excretion levels(2018-02-01) Malya, FATMA ÜMİT; Kadioglu, HÜSEYİN; Hasbahçeci, Mustafa; Dolay, KEMAL; Guzel, MEHMET; Ersoy, YELİZ EMİNE; MALYA, FATMA ÜMİT; KADIOĞLU, HÜSEYİN; DOLAY, KEMAL; GÜZEL, MEHMET; ERSOY, YELIZ EMINEObjective To compare urinary iodine excretion levels in patients with breast cancer and control subjects. Methods In this prospective pilot study, patients with breast cancer and normal controls were recruited. Age and menopausal status were recorded. Levels of serum thyroid-stimulating hormone, blood urea nitrogen and creatinine and urine iodine concentration (UIC) were measured. UIC levels were divided into three categories: low (<100 µg/l), normal (100-200 µg/l) or high (>200 µg/l). Results A total of 24 patients with breast cancer and 48 controls were included in the study. There were no statistically significant differences between the two groups with regard to thyroid-stimulating hormone, blood urea nitrogen or creatinine levels. When considered overall, there was no statistical difference in UIC between patients and controls. However, comparisons within each category (low, normal or high UIC) showed a significantly higher percentage of patients with breast cancer had a high UIC compared with controls. Conclusions A high UIC was seen in a significantly higher percentage of patients with breast cancer than controls. UIC may have a role as a marker for breast cancer screening. Further studies evaluating UIC and iodine utilization in patients with breast cancer are warranted.Publication Metadata only Feasibility of breast conserving surgery in multifocal breast cancers(2014-09-01) Kadioglu, HÜSEYİN; YUCEL, Serap; Yildiz, Seyma; Bozkurt, SÜLEYMAN; Ersoy, YELİZ EMİNE; SAGLAM, Esra; MUSLUMANOGLU, Mahmut; KADIOĞLU, HÜSEYİN; YILDIZ, ŞEYMA; BOZKURT, SÜLEYMAN; ERSOY, YELIZ EMINEBACKGROUND: Multifocal breast cancers (MFBCs) present a challenge to surgeons. Although its feasibility is still controversial, breast-conserving surgery (BCS) is not contraindicated for MFBCs. The investigators retrospectively evaluated the feasibility of BCS and reviewed histopathologic findings in patients with MFBC.Publication Open Access Ischemia Modified Albumin Can Predict Necrosis at Incarcerated Hernias(2013-01-01) Kadioglu, HÜSEYİN; Omur, Dilek; Bozkurt, SÜLEYMAN; FERLENGEZ, Ekrem; Memmi, NAİM; Ersoy, YELİZ EMİNE; CIPE, Gokhan; Muslumanoglu, Mahmut; KADIOĞLU, HÜSEYİN; BOZKURT, SÜLEYMAN; MEMMİ, NAİM; ERSOY, YELIZ EMINEPurpose. To evaluate the predictive effect of IMA in incarcerated hernias. Methods. Three groups (𝑛=7) of rats were operated. Group I aimed to mimic incarceration, group II aimed the strangulation, and group III was the sham group. IMA and LDH measurements were made. Results. IMA levels were significantly higher in strangulation mimicking group and IMA levels were normal at postoperative 6th hour in incarceration mimicking group. LDH levels were significantly higher in both incarceration and strangulation mimicking groups. Conclusion. IMA seems to be an effective marker in incarcerated hernias to predict necrosis. But we need further studies to generalise this hypothesis.